Neko Health raised $700 million in a Series C round at a valuation near $7 billion, per the funding coverage. The Stockholm-based company, co-founded by Spotify's Daniel Ek and Hjalmar Nilsonne, sells a full-body scan covering skin, heart, and blood markers, processed with AI to flag health risks before symptoms appear.
The read is what $7 billion actually prices. Neko runs a handful of clinics on a waitlist model, so the valuation underwrites a thesis, with current revenue nowhere near it. The thesis has three legs: that preventive diagnostics becomes a real consumer category, that accumulated scan data compounds into a defensible model, and that Ek's consumer-brand track record carries from music into health. The Ek halo lowers Neko's cost of capital, and a $700 million round buys years of clinic-expansion runway before the model has to prove itself.
The risk on the cap table is the one every hardware-plus-clinic health startup faces. Physical scale is slow and capital-intensive, regulatory clearance varies country by country, and a body-scan business does not compound the way software does. At $7 billion ahead of profit, the next round or an eventual listing needs the clinic count and repeat-scan retention to justify the mark. For now the round says late-stage investors believe preventive scanning is a durable category.
Bottom Line
Seven billion dollars is a bet that preventive body-scanning becomes routine consumer healthcare. Watch clinic count and repeat-scan retention, and discount the founder's name, for whether it holds.